Browse the corpus

REFERENCES Campbell PJ, Bareford D, Erber WN, et al, “Reticulin Accumulation in Essential Thrombocythemia: Prognostic Significance and Relationship to Therapy,” J Clin Oncol , 2009, 27(18):2991-9. [PubMed 19364963 ] Doubek M, Brychtova Y, Doubek R, et al, “Anagrelide Therapy in Pregnancy: Report of a Case of Essential Thrombocythemia,” Ann Hematol , 2004, 83(11):726-7. [PubMed 15278298 ] Fruchtman SM, Petitt RM, Gilbert HS, et al, “Anagrelide: Analysis of Long-Term Efficacy, Safety and Leukemogenic Potential in Myeloproliferative Disorders,” Leuk Res , 2005, 29(5):481-91. [PubMed 15755500 ] Harrison CN, Campbell PJ, Buck G, et al, “Hydroxyurea Compared With Anagrelide in High-Risk Essential Thrombocythemia,” N Engl J Med , 2005, 353(1):33-45. [PubMed 16000354 ] Pescatore SL and Lindley C, “Anagrelide: A Novel Agent for the Treatment of Myeloproliferative Disorders,” Expert Opin Pharmacother , 2000, 1(3):537-46. [PubMed 11249536 ] Silver RT, “Anagrelide is Effective in Treating Patients With Hydroxyurea-Resistant Thrombocytosis in Patients With Chronic Myeloid Leukemia,” Leukemia , 2005, 19(1):39-43. [PubMed 15510207 ] Steurer M, Gastl G, Jedrzejczak WW, et al, Anagrelide for Thrombocytosis in Myeloproliferative Disorders: A Prospective Study to Assess Efficacy and Adverse Event Profile,” Cancer, 2004, 101(10):2239-46. [PubMed 15476273 ] Tefferi A and Vardiman JW, “Classification and Diagnosis of Myeloproliferative Neoplasms: The 2008 World Health Organization Criteria and Point-of-Care Diagnostic Algorithms,” Leukemia , 2008, 22(1):14-22. [PubMed 17882280 ] Topic 8593 Version 41.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0503-189.41.172.26-E56BECDC24-S244013.14]